CMMB sentiment intelligence

Chemomab Therapeutics (CMMB) Q3 2025 earnings summary

Chemomab Therapeutics (CMMB) reported its Q3 2025 earnings, highlighting advanced preparations for its nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC) with regulatory alignment from the FDA and EMA. The company's cash reserves are expected to fund operations throu

Tone

Positive 72/100

Event

Earnings

Published

21 Jul 2026 05:42

Source

Quartr

Chemomab Therapeutics (CMMB) Q4 2025 earnings summary

Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced

Tone

Positive 80/100

Event

Earnings

Published

20 Jul 2026 05:42

Source

Quartr

Chemomab Therapeutics (CMMB) Q1 2026 earnings summary

Chemomab Therapeutics (CMMB) reported its Q1 2026 earnings, highlighting new clinical data supporting nebokitug's potential as a disease-modifying drug for PSC and IBD, and ongoing partnering discussions. The company's cash reserves of $8.0 million are expected to fund operations

Tone

Positive 71/100

Event

Earnings

Published

19 Jul 2026 02:40

Source

Quartr

Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to F

Tone

Positive 92/100

Event

Earnings

Published

18 Jul 2026 21:40

Source

Quartr

Chemomab Therapeutics (CMMB) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Chemomab Therapeutics (CMMB) presented a summary of their Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025. Key highlights include positive Phase II results for CM-101 (Nebokitug) in primary sclerosing cholangitis (PSC), with an FDA regulatory path and additional

Tone

Positive 76/100

Event

Earnings

Published

16 Jul 2026 22:41

Source

Quartr

HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan

HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which in

Tone

Positive 63/100

Event

Deals and strategy

Published

16 Jul 2026 19:41

Source

Stock Titan

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $5

Tone

Positive 66/100

Event

Analyst action

Published

14 Jul 2026 16:31

Source

Moomoo

Chemomab Therapeutics, Scipher Medicine to Merge in All-Stock Deal

Chemomab Therapeutics and Scipher Medicine have announced an all-stock merger, aiming to create a combined company focused on precision immunology. The deal is expected to close in the second half of 2026, with Scipher Medicine shareholders owning approximately 80% of the new ent

Tone

Positive 71/100

Event

Deals and strategy

Published

09 Jul 2026 15:12

Source

Moomoo

Chemomab, Scipher Bet On Taking AI-Powered Precision Medicine Into Immunology

Chemomab and Scipher are merging to combine their expertise in AI and precision medicine for applications in immunology. This strategic move aims to leverage advanced technologies to revolutionize the treatment of immune disorders. The collaboration seeks to enhance drug developm

Tone

Positive 70/100

Event

Balance sheet

Published

08 Jul 2026 20:40

Source

Scrip

Chemomab Therapeutics (CMMB) M&A announcement Summary

Chemomab Therapeutics announced a merger with Scipher, combining AI-powered precision medicine with Chemomab's anti-CCL24 antibody to target rheumatoid arthritis. The all-stock transaction will result in Chemomab shareholders owning approximately 32% of the combined company, with

Tone

Positive 70/100

Event

Deals and strategy

Published

08 Jul 2026 18:40

Source

Quartr

Chemomab and Scipher Medicine agree biotechnology merger

Chemomab Therapeutics and Scipher Medicine have announced a stock-based merger, forming Scipher Medicine Corporation, which will focus on advancing nebokitug, an anti-CCL24 antibody, into an AI-guided Phase 2 rheumatoid arthritis trial. The combined company is valued at approxima

Tone

Positive 67/100

Event

Deals and strategy

Published

08 Jul 2026 16:40

Source

grafa.com

CMMB Stock Surges As Traders Target Biotech Momentum

Shares of Chemomab Therapeutics Ltd. (CMMB) have recently seen significant price action, surging from around $1.50 to the high $2s, demonstrating classic low-float breakout behavior despite recent clinical trial uncertainty. The company's strong cash position relative to liabilit

Tone

Positive 64/100

Event

Analyst action

Published

08 Jul 2026 13:40

Source

www.timothysykes.com

Scipher Medicine Corporation entered into an Agreement and Plan of Merger to acquire Chemomab Therapeutics Ltd. with an enterprise value of approximately $100 million in a reverse merger transaction.

Scipher Medicine Corporation has formally agreed to acquire Chemomab Therapeutics Ltd. in a reverse merger transaction with an enterprise value of approximately $100 million. The combined entity is valued at $150 million and will be named Scipher Medicine Corporation, trading und

Tone

Positive 67/100

Event

Deals and strategy

Published

08 Jul 2026 13:39

Source

www.marketscreener.com

Chemomab and Scipher Medicine to merge in $150M deal

Chemomab Therapeutics and Scipher Medicine Corporation have announced an all-stock merger valued at $150 million, with Chemomab equity holders owning 32% and Scipher 68% of the combined company, which will operate as Scipher Medicine Corporation and trade on Nasdaq as SCIP. The d

Tone

Positive 73/100

Event

Deals and strategy

Published

08 Jul 2026 12:34

Source

Investing.com

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement to combine companies and advance nebokitug, a first-in-class anti-CCL24 antibody, into a precision medicine Phase 2 trial for rheumatoid arthritis. The combined entity, to be named Scipher Med

Tone

Positive 82/100

Event

Deals and strategy

Published

08 Jul 2026 11:40

Source

GlobeNewswire

CMMB - Chemomab Therapeutics Ltd ADR Options

This article provides a detailed financial overview of Chemomab Therapeutics Ltd. (CMMB), an ADR-listed biotechnology company. It covers key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's stock closed at

Tone

Positive 70/100

Event

Analyst action

Published

03 Jul 2026 11:39

Source

Finviz